ANT3310 is a novel diazabicyclooctane (DBO) β-lactamase inhibitor with distinct advantages over other agents in its class, designed to address the growing global threat of antibiotic resistance, particularly against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB) by inhibiting serine β-lactamases (SBLs), including OXA enzymes.